Vascular calcification - Is aldosterone a culprit?

Nephrology Dialysis Transplantation

Volumn 28, Issue 5, 2013, Pages 1080-1084

  Lang, Florian ^a   Ritz, Eberhard ^b   Voelkl, Jakob ^a   Alesutan, Ioana ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

chronic kidney disease; klotho; mineralocorticoid receptor; osteoinductive signalling; spironolactone

Indexed keywords

ALDOSTERONE; ALKALINE PHOSPHATASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE TRANSPORTER; SPIRONOLACTONE; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA;

AGING; BONE DEVELOPMENT; CHRONIC KIDNEY DISEASE; HUMAN; HYPERALDOSTERONISM; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY CALCIFICATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

CHRONIC KIDNEY DISEASE; KLOTHO; MINERALOCORTICOID RECEPTOR; OSTEOINDUCTIVE SIGNALLING; SPIRONOLACTONE;

ALDOSTERONE; ANIMALS; HUMANS; HYPERPHOSPHATEMIA; MICE; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84877957841     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft041     Document Type: Review

References (56)

1. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
2. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897
3. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633
4. Shroff RC, McNair R, Figg N et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-1757
5. Cui RR, Li SJ, Liu LJ et al. MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovasc Res 2012; 96: 320-329
6. Ellam TJ, Chico TJ. Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012; 220: 310-318
7. Hofmann Bowman MA, McNally EM. Genetic pathways of vascular calcification. Trends Cardiovasc Med 2012; 22: 93-98
8. Kanno Y, Into T, Lowenstein CJ et al. Nitric oxide regulates vascular calcification by interfering with TGF-signalling. Cardiovasc Res 2008; 77: 221-230
9. Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hy-pertens 2012; 21: 362-368
10. Lee HL, Woo KM, Ryoo HM et al. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 2010; 391: 1087-1092
11. Torres PA, De Broe M. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 2012; 82: 19-25
12. Voelkl J, Alesutan I, Leibrock CB et al. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypo-morphic mice. J Clin Invest 2013 doi: 10.1172/JCI64093. [Epub ahead of print January 9, 2013]
13. Wu SY, Yu YR, Cai Y et al. Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood) 2012; 237: 31-37
14. Lau WL, Leaf EM, Hu MC et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012; 82: 1261-1270
15. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell pheno-typic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154
16. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-1059
17. Sun Y, Byon CH, Yuan K et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 2012; 111: 543-552
18. Al-Aly Z. Vascular calcification in uremia: what is new and where are we going? Adv Chronic Kidney Dis 2008; 15: 413-419
19. Nowik M, Picard N, Stange G et al. Renal phosphaturia during metabolic acidosis revisited: molecular mechanisms for decreased renal phosphate reabsorption. Pflugers Arch 2008; 457: 539-549
20. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912
21. Villa-Bellosta R, Levi M, Sorribas V. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. Pflugers Arch 2009; 458: 1151-1161
22. Shao JS, Cheng SL, Pingsterhaus JM et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210-1220
23. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25: 187-191
24. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136
25. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51
26. Fischer SS, Kempe DS, Leibrock CB et al. Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol 2010; 299: F1171-F1177
27. Lim K, Lu TS, Molostvov G et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243-2255
28. Takei Y, Yamamoto H, Sato T et al. Stanniocalcin 2 is associated with ectopic calcification in alpha-klotho mutant mice and inhibits hyperphosphatemia-induced calcification in aortic vascular smooth muscle cells. Bone 2012; 50: 998-1005
29. Jaffe IZ, Tintut Y, Newfell BG et al. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 2007; 27: 799-805
30. Suzuki J, Iwai M, Mogi M et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 917-921
31. Cooper JN, Tepper P, Barinas-Mitchell E et al. Serum aldosterone is associated with inflammation and aortic stiffness in normoten-sive overweight and obese young adults. Clin Exp Hypertens 2012; 34: 63-70
32. de Rita O, Hackam DG, Spence JD. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol 2012; 28: 706-711
33. Hillaert MA, Lentjes EG, Kemperman H et al. Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 2012. [Epub ahead of print June 22, 2012]
34. Sanz-Rosa D, Cediel E, De las Heras N et al. Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. J Hypertens 2005; 23: 1167-1172
35. Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant 2012; 27: 2650-2657
36. Calvier L, Miana M, Reboul P et al. Galectin-3 mediates aldoster-one-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013; 33: 67-75
37. Newfell BG, Iyer LK, Mohammad NN et al. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and-independent pathways. Arterioscler Thromb Vasc Biol 2011; 31: 1871-1880
38. Quaschning T, Ruschitzka F, Shaw S et al. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001; 37: 801-805
39. Zhao MM, Xu MJ, Cai Y et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int 2011; 79: 1071-1079
40. Hene RJ, Boer P, Koomans HA et al. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101
41. Kendrick J, Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis 2011; 58: 826-834
42. Kuro O. Phosphate and Klotho. Kidney Int Suppl 2011; 79: S20-S23
43. Koleganova N, Piecha G, Ritz E et al. Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2488-2496
44. Shroff R. Phosphate is a vascular toxin. Pediatr Nephrol 2012. [Epub ahead of print November 17, 2012]
45. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
46. Aoshima Y, Mizobuchi M, Ogata H et al. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-alpha. Nephrol Dial Transplant 2012; 27: 1800-1806.
47. Cohen-Lahav M, Shany S, Tobvin D et al. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant 2006; 21: 889-897
48. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: patho-physiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev 2010; 3: 109-121
49. London GM. Bone-vascular cross-talk. J Nephrol 2012; 25: 619-625
50. Nitta K, Akiba T, Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients Am J Med 2003; 15: 115-250
51. Zoccali C, Ruggenenti P, Perna A et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930
52. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912-919
53. Guney I, Selcuk NY, Altintepe L et al. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail 2009; 31: 779-784
54. Bomback AS, Klemmer PJ. Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012; 33: 119-124
55. Buysse JM, Huang IZ, Pitt B. PEARL-HF: prevention of hyperka-lemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012; 8: 17-28
56. Edwards NC, Steeds RP, Chue CD et al. The safety and tolerabil-ity of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012; 73: 447-454